Canada Pension Plan Investment Board’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-444,900
Closed -$15.8M – 1425
2025
Q2
$15.8M Buy
+444,900
New +$14.4M 0.01% 511
2024
Q1
– Sell
-457,490
Closed -$27.5M – 1216
2023
Q4
$27.5M Hold
457,490
– – 0.03% 348
2023
Q3
$30.7M Sell
457,490
-9,100
-2% -$632K 0.04% 314
2023
Q2
$32.2M Buy
466,590
+335,600
+256% +$21.9M 0.05% 284
2023
Q1
$6.32M Sell
130,990
-281,800
-68% -$13.8M 0.01% 538
2022
Q4
$20.6M Buy
412,790
+1,400
+0.3% +$67.8K 0.04% 321
2022
Q3
$16.8M Buy
411,390
+308,800
+301% +$14.5M 0.03% 366
2022
Q2
$5.64M Sell
102,590
-154,710
-60% -$6.53M 0.01% 515
2022
Q1
$9.35M Buy
257,300
+40,500
+19% +$1.6M 0.01% 509
2021
Q4
$10.1M Buy
216,800
+188,200
+658% +$9.55M 0.01% 575
2021
Q3
$1.45M Buy
+28,600
New +$1.19M ﹤0.01% 910
2021
Q2
– Sell
-125,900
Closed -$3.65M – 1274
2021
Q1
$3.65M Buy
+125,900
New +$3.43M ﹤0.01% 702

Other funds holding LEGN

Canada Pension Plan Investment Board's LEGN Position: Q3 2025 in Review

Canada Pension Plan Investment Board sold out of Legend Biotech (LEGN) in Q3 2025, closing a stake of 444,900 shares — an estimated $15.8M sold.

Canada Pension Plan Investment Board first reported a position in LEGN in Q1 2021 and held it in 12 quarters. The position peaked at $32.2M in Q2 2023. 200 funds tracked by Wall St. Rank hold LEGN as of Q3 2025.

  • Canada Pension Plan Investment Board reported no remaining Legend Biotech position as of Q3 2025 after selling out during the quarter.
  • Canada Pension Plan Investment Board sold 444,900 Legend Biotech shares in Q3 2025, an estimated $15.8M.
  • Canada Pension Plan Investment Board first reported a position in Legend Biotech in Q1 2021 and held it in 12 quarters.
  • Canada Pension Plan Investment Board's Legend Biotech position peaked at $32.2M in Q2 2023.
  • 200 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2025.

Based on Canada Pension Plan Investment Board's 13F filing for Q3 2025, filed 13 Nov 2025.